Journey Medical Corporation to Participate in September 2025 Investor Conferences

Journey Medical Corporation, a commercial-stage pharmaceutical company listed on Nasdaq under the ticker DERM, is set to engage with investors at two key conferences in September 2025. The company's Co-Founder, President, and CEO, Claude Maraoui, will represent Journey Medical at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, at 1:30 p.m. ET in New York City, where he will participate in a fireside chat and one-on-one meetings. Additionally, he will join the Lake Street Capital Markets 9th Annual Best Ideas Growth (BIG9) Conference on September 11, 2025, also in New York City, focusing on one-on-one meetings with investors.

Journey Medical Corporation specializes in the marketing and sale of FDA-approved prescription pharmaceuticals aimed at treating various dermatological conditions. With a well-defined sales and marketing strategy, the company currently offers eight branded medications that address common skin issues. The experienced team at Journey Medical has a significant background in developing and commercializing well-known dermatological brands, positioning the company favorably within the healthcare market.

Founded by Fortress Biotech, Inc., Journey Medical is headquartered in Scottsdale, Arizona. The company adheres to the regulatory requirements as a publicly traded entity, filing periodic reports with the SEC. For more information about Journey Medical and its product offerings, stakeholders are encouraged to visit their official website.

With these upcoming conferences, Journey Medical aims to enhance its visibility and foster relationships with potential investors, emphasizing its commitment to healthcare innovation within the dermatology sector. For further inquiries, interested parties can contact Jaclyn Jaffe for investor relations and Tony Plohoros for media relations.

As Journey Medical Corporation ("Journey Medical") prepares to participate in two prominent investor conferences this September, investors should carefully consider the implications of the company’s strategic outreach and its market position in the dermatological pharmaceutical space.

Journey Medical, listed on Nasdaq (DERM), operates in a critical sector focused on FDA-approved dermatological treatments, a market characterized by robust demand and ongoing innovation. The participation of Claude Maraoui, Co-Founder and CEO, in events such as the H.C. Wainwright 27th Annual Global Investment Conference and the Lake Street Capital Markets BIG9 Conference, emphasizes the company's commitment to transparency and investor engagement. This can be a positive signal for investors, suggesting management's confidence in the company’s current performance and future prospects.

With eight branded prescription drugs aimed at common skin conditions, Journey Medical has a diversified portfolio, which can mitigate risks associated with reliance on a few products. Moreover, the dermatology sector is particularly attractive due to rising awareness of skin health and advancements in treatment options, representing opportunities for sustained growth.

However, investors should remain vigilant about competitive pressures within the pharmaceutical industry, especially given the rapid pace of innovation and the number of emerging players. It’s essential to analyze the company’s pipeline for new products and its ability to maintain market share. Financial health metrics, including revenue growth, profit margins, and research & development expenditures, should also be monitored closely in the lead-up to these conferences.

In conclusion, Journey Medical's active engagement in investor relationships, combined with its niche focus in the dermatology sector, presents a cautiously optimistic investment opportunity. Investors should await insights from the upcoming conferences, which may provide further clarity on strategic direction and financial performance, reinforcing or re-evaluating their positions in the stock.